primary sclerosing cholangitis - clinical studies - oslo 14.6.2010 u. beuers academic medical...
TRANSCRIPT
![Page 1: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/1.jpg)
Primary Sclerosing Cholangitis
- Clinical Studies -
Oslo14.6.2010
U. Beuers Academic Medical Center, Univerity of Amsterdam, NL
![Page 2: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/2.jpg)
Primary Sclerosing Cholangitis
Bile duct stenoses
Aggravation of injury by BA
Cholestasis with retention of hydrophobic bile acids in liver
Liver cell damage, apoptosis, necrosis, fibrosis, cirrhosis
Liver failure
Immunologic bile duct injury
(Cytokine-mediated)
Pathogenetic model
m, 42 J.
![Page 3: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/3.jpg)
• Study design, inclusion criteria, endpoints
• Medical approaches• (3 min Christoph Schramm)
• Endoscopic approaches• (3 min Cyriel Ponsioen)
• Surgical approaches• (3 min Martti Faerkkila)
Primary Sclerosing Cholangitis
![Page 4: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/4.jpg)
• Study design, inclusion criteria, endpoints
• Medical approaches
• Endoscopic approaches
• Surgical approaches
Primary Sclerosing Cholangitis
![Page 5: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/5.jpg)
Treatment of Primary Sclerosing Cholangitis
Bile duct stenoses
Aggravation of injury by BA
Cholestasis with retention of hydrophobic bile acids in liver
Liver cell damage, apoptosis, necrosis, fibrosis, cirrhosis
Liver failure
Immunologic bile duct injury
(Cytokine- mediated)
Pathogenetic model Placebo-contr.Studies Pilot studies
Cyclosporine
Methotrexate
Infliximab
D-Penicillamine
Colchicin
Budesonide
Cladribin
Etanercept
MMF
Nicotine
Pentoxifylline
Prednisone
Tacrolimus
Pirfenidone
![Page 6: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/6.jpg)
Treatment of Primary Sclerosing Cholangitis
Bile duct stenoses
Aggravation of injury by BA
Cholestasis with retention of hydrophobic bile acids in liver
Liver cell damage, apoptosis, necrosis, fibrosis, cirrhosis
Liver failure
Immunologic bile duct injury
(Cytokine- mediated)
Placebo-contr.Studies Pilot studies
Cyclosporine
Methotrexate
Infliximab
D-Penicillamine
Colchicin
Budesonide
Cladribin
Etanercept
MMF
Nicotine
Pentoxifylline
Prednisone
Tacrolimus
Pirfenidone
Pathogenetic model
![Page 7: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/7.jpg)
Bile duct stenoses
Aggravation of injury by BA
Cholestasis with retention of hydrophobic bile acids in liver
Liver cell damage, apoptosis, necrosis, fibrosis, cirrhosis
Liver failure
PSC : Therapy
Immunologic bile duct injury
(Cytokine- mediated)
Pathogenetic model
Ursodeoxycholic acid(15-20 mg/kg/d)
?
![Page 8: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/8.jpg)
Treatment of Primary Sclerosing Cholangitis with UDCA - Serum liver tests -
Beuers et al., Hepatology 1992;16:707
Change[%]
BilirubinPlacebo
UDCA
Gamma - GT
Alk. Phosphatase
Months
P<0.05
P<0.01
P<0.01
n=14
![Page 9: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/9.jpg)
Treatment of Primary Sclerosing Cholangitis with UDCA - Placebo-controlled studies -
München Mayo Oxford Scandinavia Mayo(1992) (1997) (2001) (2005) (2009)
Dose [mg/kg/d] 13-15 13-15 20 17-23 28-30(n=14) (n=105) (n=24) (n=219) (n=150)
Duration [years] 1 2.2 2 5 5
Symptoms - - - - -
Serum liver tests + + + - +
Histology + + - -
Beuers et al., Hepatology 1992;16:707Lindor et al., New Engl J Med 1997;336:691Mitchell et al., Gastroenterology 2001;121:900Olsson et al. Gastroenterology 2005;129:1464Lindor et al., Hepatology 2009;50:1
![Page 10: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/10.jpg)
Olsson et al., Gastroenterology 2005;129:1464
[%] Placebo (n=101)
UDCA (n=97)
Survivalwithout
livertrans-
plantation
Study daysPower analysis a priori: n = 346
p = 0.37
Treatment of Primary Sclerosing Cholangitis with UDCA - Transplant-free survival -
![Page 11: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/11.jpg)
Cullen et al., J Hepatol 2008;48:792
Treatment of Primary Sclerosing Cholangitis with UDCADoubleblind, randomized, placebo-controlled dose finding study: Oxford/Munich
- Serum Alkaline Phosphatase -
* p<0.05
![Page 12: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/12.jpg)
Lindor et al., Hepatology 2009;50:1 n=150
Treatment of Primary Sclerosing Cholangitis with UDCADouble blind, randomized, placebo-controlled trial
- High dose UDCA (30 mg/kg/d) for 5 years -
![Page 13: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/13.jpg)
Treeprasertsuk et al., Hepatology 2010:51:1302 n=150
Treatment of Primary Sclerosing Cholangitis with UDCADouble blind, randomized, placebo-controlled trial
- High dose UDCA (30 mg/kg/d) for 5 years -
Patient population:
41.3% (62) Advanced liver fibrosis / cirrhosis
58.7% (88) Mild liver fibrosis
![Page 14: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/14.jpg)
Treatment of PSCEASL Clinical Practice Guidelines
• The available data base shows that UDCA (15-20 mg/kg/d) improves serum liver tests and surrogate markers of prognosis (I/B1), but does not reveal a proven benefit on survival (III/C2). The limited data base does not yet allow a specific recommendation for the general use of UDCA in PSC.
• I : Randomized, placebo-controlled trials, meta-analyses• III : Opinion of respected authorities• B1 : Moderate evidence – strong recommendation (GRADE)• C2 : Weak evidence - weak recommendation (GRADE)
EASL Clinical Practice Guidelines, J Hepatol 2009;51:237
![Page 15: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/15.jpg)
Treatment of PSCAASLD Clinical Practice Guidelines
• In adult patients with PSC, we recommend against the use of UDCA as medical therapy (IA).
• In adult patients with PSC and overlap syndrome,we recommend the use of corticosteroids and other immunosuppressive agents for medical therapy (IC)
• I A : Strong recommendation – strong evidence • I C : Strong recommendation – weak evidence
Chapman et al., AASLD PG PSC. Hepatology 2010;51:660
![Page 16: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/16.jpg)
Bile duct stenoses
Aggravation of injury by BA
Cholestasis with retention of hydrophobic bile acids in liver
Liver cell damage, apoptosis, necrosis, fibrosis, cirrhosis
Liver failure
PSC : Future Therapy
Immunologic bile duct injury
(Cytokine- mediated)
Pathogenetic model
Antibiotics ?
Docahexanoic acid ?
Immunosuppresive agents ?
Nor-Ursodeoxycholic acid ?
ACE Inhibitors ?
Nuclear receptor agonists ?- PXR- FXR- VDR- PPAR
![Page 17: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/17.jpg)
• Study design, inclusion criteria, endpoints
• Medical approaches
• Endoscopic approaches
• Surgical approaches
Primary Sclerosing Cholangitis
![Page 18: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/18.jpg)
Bile duct stenoses
Aggravation of injury by BA
Cholestasis with retention of hydrophobic bile acids in liver
Liver cell damage, apoptosis, necrosis, fibrosis, cirrhosis
Liver failure
PSC : Therapy
Immunologic bile duct injury
(Cytokine- mediated)
Pathogenetic model
Endoscopic dilatation
![Page 19: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/19.jpg)
Treatment of PSCEASL Clinical Practice Guidelines
• Dominant bile duct strictures with significant cholestasis should be treated with biliary dilatation (II-2/B1).
• Biliary stent insertion should be reserved for cases where stricture dilatation and biliary drainage are unsatisfactory (III/C2).
• Prophylactic antibiotic coverage is recommended in this setting (III/C1).
• II-2 : Cohort- and case-control studies• III : Opinion of respected authorities• B1 : Moderate evidence – strong recommendation (GRADE)• C1/2 : Weak evidence - strong/weak recommendation (GRADE)
EASL Clinical Practice Guidelines, J Hepatol 2009;51:237
![Page 20: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/20.jpg)
Treatment of PSCAASLD Practice Guidelines
• In patients with increases in serum bilirubin and/or worsening pruritus progressive bile duct dilatation on imaging studies, and/or cholangitis, we recommend performing an ERC promptly to exclude a dominant stricture (IB).
• In patients with dominant strictures from PSC, we recommend initial management with endoscopic dilatation with or without stenting (IB).
• We recommend antimicrobial therapy with correction of bile duct obstruction in dominant strictures to effectively resolve cholangitis (IA).
• IA : Strong recommendation – strong evidence (GRADE)• IB : Strong recommendation – moderate evidence (GRADE)
Chapman et al., AASLD PG PSC. Hepatology 2010;51:660
![Page 21: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/21.jpg)
• Study design, inclusion criteria, endpoints
• Medical approaches
• Endoscopic approaches
• Surgical approaches
Primary Sclerosing Cholangitis
![Page 22: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/22.jpg)
Bile duct stenoses
Aggravation of injury by BA
Cholestasis with retention of hydrophobic bile acids in liver
Liver cell damage, apoptosis, necrosis, fibrosis, cirrhosis
Liver failure
PSC : Therapy
Immunologic bile duct injury
(Cytokine- mediated)
Pathogenetic model
Liver transplantation
![Page 23: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/23.jpg)
Recurrence of PSC after Liver TransplantationProtection by Colectomy?
Alabraba et al., Liver Transpl 2009; 15: 330
![Page 24: Primary Sclerosing Cholangitis - Clinical Studies - Oslo 14.6.2010 U. Beuers Academic Medical Center, Univerity of Amsterdam, NL](https://reader030.vdocument.in/reader030/viewer/2022032707/56649e2e5503460f94b1e529/html5/thumbnails/24.jpg)
Bile duct stenoses
Aggravation of injury by BA
Cholestasis with retention of hydrophobic bile acids in liver
Liver cell damage, apoptosis, necrosis, fibrosis, cirrhosis
Liver failure
PSC : Therapy
Immunologic bile duct injury
(Cytokine- mediated)
Pathogenetic model
Liver transplantation
Endoscopic dilatation
Ursodeoxycholic acid
(15-20 mg/kg/d)